Clinical Trial Update: A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism [Phase 3]

View source ↗

Summary

A Phase 3 randomized clinical trial is evaluating the safety and efficacy of Palopegteriparatide at doses greater than 30 μg/day in adults with hypoparathyroidi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• Palopegteriparatide (palopegteriparatide)

Snippet

Sponsor: Ascendis Pharma Bone Diseases A/S | Conditions: Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Status: RECRUITING